EP Patent

EP4112041A1 — Micellar solution comprising diclofenac

Assigned to Haleon CH SARL · Expires 2023-01-04 · 3y expired

What this patent protects

There are provided novel topical or transdermal nano-formulations of diclofenac. The formulations are in the form of micellar solutions. The micellar solutions comprise diclofenac alkali metal salt, in a concentration of about 2% to about 5.5% (w/w), a solvent, a mixture of surfa…

USPTO Abstract

There are provided novel topical or transdermal nano-formulations of diclofenac. The formulations are in the form of micellar solutions. The micellar solutions comprise diclofenac alkali metal salt, in a concentration of about 2% to about 5.5% (w/w), a solvent, a mixture of surfactants, and an aqueous continuous, outer phase. The micellar solution may optionally further comprise permeation enhancers. The micellar solutions can be gelled with a suitable gelling agent. The compositions disclosed are useful in the treatment of joint pain, osteoarthritis, muscle pain, back pain and/or inflammation.

Drugs covered by this patent

Patent Metadata

Patent number
EP4112041A1
Jurisdiction
EP
Classification
—
Expires
2023-01-04
Drug substance claim
No
Drug product claim
No
Assignee
Haleon CH SARL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.